Objective: To evaluate the association between surgical menopause (SM) versus natural menopause (NM) in relation to later left ventricular (LV) structure and function, while taking into account the LV parameters and other cardiovascular disease risk factor (CVDRF) levels that predate the menopausal transition.
T he association of surgical menopause (SM) with cardiovascular disease (CVD) outcomes is unclear. SM, defined as menstrual cessation due to hysterectomy with ovarian conservation (HOC) or bilateral oophorectomy (HBSO), reduces a woman's exposure to endogenous estrogen before age of natural menopause (NM).
1,2 Some studies have proposed that this estrogen deficiency may explain the elevated CVD risk among women with SM, especially women with HBSO. 3, 4 However, evidence suggests that women who undergo SM tend to have adverse cardiovascular disease risk factors (CVDRFs) long before the onset of menopause, which may account for their elevated risk of CVD events in later life. 5, 6 Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) study 5 and the Study of Women's Health across the Nation (SWAN) 6 showed that accounting for presurgical CVDRF levels attenuated the observed significant differences in postmenopausal CVDRF levels between women with NM and SM.
Left ventricular (LV) structure and function is a strong predictor of several future CVD events, [7] [8] [9] but evidence for the long-term association of SM with cardiac structure and function is lacking. Reports based on rodent models suggest acute adverse effects of SM on cardiac structure and function, namely increased LV filling pressures and myocardial remodeling leading to diastolic dysfunction. [10] [11] [12] Therefore, the aim of this study was to evaluate the association of SM compared with NM with echocardiographic parameters of LV structure and function, accounting for antecedent CVDRF levels.
METHODS

Study population
The CARDIA study is a multicenter longitudinal study of 5,115 (2,787 women) adults aged 18 to 30 years, who were recruited in 1985 to 1986 from four US urban centers (Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California) to examine cardiovascular risk factor trends in young adults. The sample was recruited to be balanced on sex, race (white or black), age (18-24 or 25-30 years) , and education ( 12, >12 years). To date, seven follow-up examinations have occurred after baseline, with 72% of the surviving cohort attending the year 25 examination. Details of the study design and methods have been described elsewhere. 13 Of the 2,278 eligible nonpregnant women without SM or valvular disease at the year 5 examination (baseline for this analysis), 1,737 of them also attended the year 25 examinations (follow-up examination for this analysis). Women who did not attend year 25 visit were more likely to be of black race, younger, and current smokers, and to have fewer years of education at baseline. These two time points were chosen since echocardiography was performed on the entire cohort at years 5 (1990-1991) and 25 (2010-2011) examinations. Among the 1,737 women, we excluded those who were premenopausal or perimenopausal at year 25 examinations (n ¼ 842) or who reported menstrual cessation due to other reasons (n ¼ 50), and also women who had poor echocardiographic images. This resulted in an analytic sample of 825 women (Fig. 1) . All participants provided written informed consent with data collection, and cohort follow-up protocols were approved by the Institutional Review Boards of each field center, and also the Coordinating Center.
Measures
At every CARDIA examination, standardized protocols were used to collect information on demographics, anthropometrics, lifestyle and behavioral factors, medical history, biomarkers, and medication use from participants. Women were additionally asked if they were currently pregnant or breastfeeding, age at menarche, regularity of their menstrual period, gynecological surgeries, and use of oral contraceptives or hormone therapy for menopausal symptoms. Women reporting no menstrual cycles within the previous 12 months before their follow-up examination were considered postmenopausal in accordance with the World Health Organization criteria.
14 Among postmenopausal women, those who reported cessation of menstrual bleeding not preceded by hysterectomy, radiation, or chemotherapy were classified as having NM, whereas those who reported menstrual cessation due to hysterectomy with or without self-reported bilateral oophorectomy (BSO) were classified as having SM.
Age at final menstrual period (FMP) was defined as selfreported age at natural cessation of menstrual flow or age at surgery to remove the uterus and/or ovaries. When the FMP was unknown, it was set to the age at clinic visit at which participant first reported having undergone NM or SM.
At baseline, blood pressure was measured using a randomzero sphygmomanometer with participants seated and after 5 minutes of rest. At the 20-year follow-up examination, blood pressure was measured using an Omron aneroid device (Omron Healthcare Inc., Lake Forest, IL) and calibrated to the random-zero measures. 15 The average of the second and third consecutive measurements was used for analysis. Cigarette smoking was assessed by means of an interviewer-administered tobacco questionnaire. 16 Body mass index (BMI) was calculated by dividing weight in kilograms by height in meters squared. Waist circumference was measured to the nearest 0.5 cm at the level of the umbilicus. Physical activity level was assessed using a modified version of the Minnesota Leisure Time Physical Activity Questionnaire, with total scores representing total moderate-to-vigorous activity expressed in exercise units. Family history of coronary heart disease was defined as a positive parental history of heart attack. Alcohol intake was defined as consumption of any alcoholic beverages in the past year. Lipid levels were assessed from fasting blood. Plasma total 
Echocardiography
Echocardiography was performed using an Acuson cardiac ultrasound system (Siemens) at baseline and Artida cardiac ultrasound scanner (Toshiba Medical Systems, Otawara, Japan) at the follow-up examination by trained sonographers. A reliability study conducted in a subset of the cohort showed good agreement between repeated echocardiographic measures. 17 Left ventricular mass (LVM) was calculated using the Devereux formula 18 and indexed to body surface area. LV mass-to-volume ratio (LVMVR) was calculated by dividing LVM by LV end-diastolic volume. Cardiac output was determined as the product of stroke volume and heart rate. LV ejection fraction (LVEF) was calculated as the ratio of stroke volume to end-diastolic volume. E/A ratio was calculated as the ratio of mitral peak early (E) to late (A) diastolic filling velocity. Peak early diastolic mitral annular velocity (e') was calculated from the average of the septal and lateral mitral annular velocities.
At the follow-up examination, two-dimensional speckletracking echocardiography (STE) for myocardial strain was also performed and analyzed using two-dimensional wall motion tracking software (UltraExtend Version 2.7, Toshiba Medical Systems, Otawara, Japan). Strain was calculated as the change in segment length relative to its end-diastolic length from peak systolic values. 19 Global strain values were calculated as the average of segmental peak systolic strain.
More negative values of global longitudinal and circumferential peak strain indicate greater shortening or better function. Quality control and reproducibility profile of the CARDIA echocardiography and STE examinations have been previously described. 20 
Statistical analyses
Analytic sample characteristics at baseline, stratified by menopause status at the follow-up examination, were compared using chi-square test for categorical variables and t test for continuous variables. For analyses in which SM was further stratified by ovarian status, analysis of variance was used for quantitative measures. Differences in echocardiography parameters at the follow-up examination were determined between SM and NM using unadjusted and adjusted general linear regression models. Models were adjusted for covariates measured at baseline (age, race, education, center, BMI, waist girth, physical activity, parity, smoking status, oral contraceptives, alcohol intake, family history of CHD, systolic blood pressure, diabetes, age at menarche, HDL, and total cholesterol), and also each respective baseline echocardiographic parameter. Additional models adjusting for age at FMP and the use of hormone therapy or antihypertensive medication during 20 years of follow-up were examined. Tests for interaction between type of menopause and race for each echocardiography parameter were undertaken. P values were adjusted for multiple comparisons using Tukey-Kramer method. All statistical tests were two-sided and performed at the 0.05 level of significance using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC).
RESULTS
Description of study participants at baseline (1990-1991)
Descriptive statistics for the cohort are presented in Table 1 . Approximately 38% of women reported having undergone SM by year 25, with a third of them reporting HBSO. At baseline, when all participants were premenopausal, those who later had SM during follow-up were younger, with a greater proportion of them being black and having high school education or less compared with women who later reached NM. Additionally, at year 5, women who later had SM reached menarche at an earlier age, had higher systolic blood pressure, BMI, waist circumference, and lower levels of HDL cholesterol and physical activity. Among women who later had SM, those who had HOC were younger, with a greater proportion of them being black compared with women with HBSO ( Table 1) .
Description of study participants at follow-up examination (2010-2011)
The differences in CVDRF levels observed between women with NM and SM at year 5 persisted at year 25 (Table 2 ) with SM women, on average, reaching FMP at earlier age compared with NM women (41.8 vs 48.6 years). Compared with women with NM, a greater proportion of women with SM were on antihypertensive medications (44.5 vs 26.6). Although there was no significant difference in lipidlowering medication between women with NM and SM, the latter were observed to have lower total cholesterol levels (5.0 vs 5.2 mmol/L). With regard to women with SM, those with HOC reported an earlier age at FMP than women with HBSO. The use of hormone therapy was higher among women with HBSO (26%) compared with women with HOC (11%) or NM (9%) ( Table 2 ).
Echocardiographic parameters among study participants
Differences in parameters of LV structure and function, namely, LVM, LVMVR, cardiac output, LVEF, and E/A ratio, at year 5, between women who later reached NM or SM, were not statistically significant (data not shown). However, at the follow-up examination, women with SM had higher LV mass (158 vs 147 g), LVMVR (1.7 vs 1.5), cardiac output (4.2 vs 4.0), impaired longitudinal and circumferential strain indicative of lower LV systolic function, and higher LV filling pressures assessed by the ratio of early mitral inflow velocity to early mitral annular diastolic velocity (E/e 0 ) (Supplemental APPIAH ET AL these adverse differences appeared to be greater in women with HBSO than women with HOC (Supplemental Fig. S2 , Supplemental Digital Content 2, http://links.lww.com/ MENO/A242). Adjustment for baseline echocardiographic measures and CVDRF levels eliminated the adverse associations of SM with future LV structure and function (Table 3) . Additional adjustment for age at FMP, and also hormone therapy and antihypertensive medication use during the 20-year follow-up, did not significantly influence these findings. These results remained consistent when women with HOC or HBSO were compared with women with NM (Table 4) . Additionally, among women with SM, there were no significant differences by ovarian status for all measures of LV structure and function after accounting for antecedent CVDRF (Table 4) . Finally, we failed to identify any significant interactions between race (black/white) and type of . P values were adjusted for multiple comparisons using Tukey-Kramer method. CHD, coronary heart disease; E/A, mitral ratio of peak early (E) to late (A) diastolic filling velocity; HBSO, hysterectomy with bilateral oophorectomy; HDL, high-density lipoprotein; HOC, hysterectomy with ovarian conservation; LV, left ventricular; NM, natural menopause. a P value comparing women with natural menopause to surgical menopause (HOC þ HBSO). b P value comparing women with HBSO to women with natural menopause. 
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menopause for all the parameters of LV structure and function (Supplemental Table S1 , Supplemental Digital Content 3, http://links.lww.com/MENO/A243).
DISCUSSION In this population-based cohort study of young adult women followed for 20 years, we observed that those who underwent SM during follow-up had more adverse CVDRF levels at baseline, before surgery, compared with women who reached NM at follow-up. However, controlling for baseline CVDRF and echocardiographic parameters assessed before surgery attenuated the adverse associations of SM with future LV structure and function. These data suggest that premenopausal CVDRF levels rather than gynecologic surgery predispose women with SM to elevated future CVD risk compared with women with NM.
Menopause is characterized by physiological changes that influence several systems and organs including the cardiovascular system. Previous small studies observed that postmenopausal women had more LV systolic and diastolic dysfunction than premenopausal women. [21] [22] [23] Similarly, other case-control studies observed higher relative wall thickness and concentric LV geometric remodeling independent of high blood pressure, 24 and also lower peak early diastolic velocity E wave and mitral E/A ratio indicative of impaired LV diastolic filling 25 in postmenopausal women compared with premenopausal women. Among postmenopausal women, those who reached menopause before age 40 years have also been reported to have significant impairment in LV systolic function compared with women with onset of menopause at ages at least 50 years. 23 A limitation of all these studies is the inability to assess differences in cardiac structure and function among postmenopausal women by type of menopause, and also antecedent risk factor levels.
The long-term association of SM compared with NM with cardiac function has not been well-characterized. Results from experimental studies [10] [11] [12] in adult female rats show that the onset of SM leads to perivascular fibrosis with associated increases in LV filling pressures, myocardial remodeling characterized by LV hypertrophy, and substantial increase in LV dilatation. In evaluating LV performance using systolic time intervals assessed by electrocardiogram and carotid artery pulse tracings in 50 postmenopausal women (25 with NM and 25 with SM), Kaur et al 26 observed, in unadjusted models, impaired systolic function among women with SM compared with women with NM. Whereas there was no difference in LV ejection time between groups, SM women had longer isovolumetric contraction time and showed signs of diminished cardiac performance indicated by elevated ratio of pre-ejection period to LV ejection time, a parameter that is known to be inversely correlated with the ejection fraction measured by echocardiography. 26 Consistent with these findings, we observed in the present study lower LV systolic function by means of impaired longitudinal and circumferential peak strain assessed by two-dimensional (2D) speckle tracking echocardiography, and higher LV filling pressures in women with SM compared with NM women in unadjusted models. However, these differences in LV function, together with variations in parameters of LV structure between women with NM and SM, were observed to be explained by differences in CVDRF occurring long before the onset of menopause.
Some prior studies report that the elevated risk of CVD events in women with SM may be due to the reduction in exposure to ovarian estrogen. Estrogen deficiency after menopause has been reported to be associated with adverse levels of CVDRF in women. [27] [28] [29] Evidence from experimental studies suggests that reduced estrogen levels may directly or indirectly contribute to diastolic dysfunction and hypertensive heart diseases in postmenopausal women. 30, 31 Conversely, other studies report no difference in the circulating levels of estradiol and estrone 2,32 among women with SM compared to women with NM. Furthermore, results from trials, [33] [34] [35] assessing the influence of hormone therapy on atherosclerosis progression in recently menopausal women are equivocal which casts doubts on a cardio-protective role for estrogen in CVD development among postmenopausal women. It is possible that other processes besides ovarian estrogen deficiency contribute to both menopause and CVD incidence, and thus the observed association between SM and CVD may not be causal but may reflect residual confounding of unmeasured variables.
Different lines of evidence indicate that CVDRF, namely obesity, hypertension, dyslipidemia, and smoking in young adulthood, influence both the age at NM or indications for SM. [36] [37] [38] [39] [40] A growing body of research from CARDIA and the SWAN suggests that women who undergo SM tend to have adverse CVDRF levels long before the onset of menopause, and that accounting for these premenopausal CVDRF levels attenuate the significant differences in postmenopausal CVDRF levels between women with NM and SM. 5, 6 Accordingly, when we controlled for premenopausal CVDRF in the present study, postmenopausal differences in cardiac structure and function between women with NM and SM were eliminated. This observation suggests that perhaps the underlying pathology for the higher incidence of CVD events reported in some prior studies among women with SM may have existed long before the onset of menopause. In the present study, and also other studies, women with SM had adverse CVDRF profiles long before undergoing surgery compared with women who later on reach NM.
The strengths of this study include the use of a large population-based biracial sample, extensive assessment of CVDRF, and repeated echocardiography measurements coupled with good retention during 20 years of follow-up. Potential limitations of this study warrant consideration. First, menopause status, type, and age at onset of menopause were all self-reported, which may be subject to recall error. However, self-reported SM data have been found to have good validity in other studies (sensitivity 64%; positive predictive value 100%), with a woman's accuracy in recalling age at SM surpassing recall of age at NM. 41 Second, STE for myocardial APPIAH ET AL strain was only performed at year 25. Third, echocardiograms were done 20 years apart using different equipment, sonographers, and reading centers, which may affect comparability of the indices of LV structure and function. However, a reliability study conducted in this cohort showed good agreement between repeated echocardiographic measures. 17 Fourth, whereas LV structure and function are associated with increased risk of some types of cardiovascular events, they do not entirely represent clinical endpoints. Fifth, due to the lack of information on serially measured endogenous hormones such as estrogen and androgens during the menopausal transition, their influence on the association of type of menopause with LV structure and function could not be evaluated. Finally, results of the present study may or may not be generalizable beyond black and white women.
CONCLUSIONS We observed no significant difference in LV structure and function between women with SM or NM after accounting for antecedent CVDRF levels. Our results have important clinical and public health implications as they provide evidence that premenopausal CVDRF predispose SM women to adverse LV structure and function during the postmenopausal period rather than gynecologic surgery, resulting in SM. Therefore, implementation of risk factor management should begin early in a woman's life to reduce the risk of CVD in the postmenopausal period regardless of the type of menopause.
